ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone310-388-6706
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.56 million
Profitability
Miscellaneous
Employees100
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Chromadex (NASDAQ:CDXC) Frequently Asked Questions
What is Chromadex's stock symbol?
Chromadex trades on the NASDAQ under the ticker symbol "CDXC."
How were Chromadex's earnings last quarter?
Chromadex Corp (NASDAQ:CDXC) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The firm earned $11.10 million during the quarter, compared to analysts' expectations of $10.81 million. Chromadex had a negative return on equity of 136.15% and a negative net margin of 85.86%. View Chromadex's Earnings History.
When is Chromadex's next earnings date?
What price target have analysts set for CDXC?
2 analysts have issued 1-year target prices for Chromadex's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chromadex's share price to reach $7.00 in the next year. This suggests a possible upside of 74.6% from the stock's current price. View Analyst Price Targets for Chromadex.
What is the consensus analysts' recommendation for Chromadex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.
What are Wall Street analysts saying about Chromadex stock?
Here are some recent quotes from research analysts about Chromadex stock:
- 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (8/13/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 26.6x EV-to-EBITDA multiple applied to our 2020 EBITDA per share estimate of $0.35, discounted back at a 12% rate, which yields a price objective of approximately $7.00 per share." (4/25/2019)
Has Chromadex been receiving favorable news coverage?
Headlines about CDXC stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chromadex earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Chromadex.
Are investors shorting Chromadex?
Chromadex saw a increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,296,400 shares, an increase of 5.7% from the June 15th total of 3,118,500 shares. Based on an average trading volume of 230,200 shares, the days-to-cover ratio is presently 14.3 days. Approximately 12.3% of the company's stock are sold short. View Chromadex's Current Options Chain.
Who are some of Chromadex's key competitors?
Some companies that are related to Chromadex include Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Natural Alternatives International (NAII), Mediwound (MDWD), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ).
What other stocks do shareholders of Chromadex own?
Who are Chromadex's key executives?
Chromadex's management team includes the folowing people:
- Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
- Mr. Robert N. Fried, CEO & Director (Age 59)
- Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
- Mr. Ben Shichman, Chief Technology Officer
- Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation
Who are Chromadex's major shareholders?
Chromadex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.02%), Tieton Capital Management LLC (2.38%), Uniplan Investment Counsel Inc. (1.27%), Northern Trust Corp (0.75%), Charles Schwab Investment Management Inc. (0.16%) and Granite Investment Partners LLC (0.16%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Stephen A Block and Stephen R Allen. View Institutional Ownership Trends for Chromadex.
Which major investors are selling Chromadex stock?
CDXC stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Morgan Stanley, North Star Investment Management Corp., D.A. Davidson & CO. and Wells Fargo & Company MN. View Insider Buying and Selling for Chromadex.
Which major investors are buying Chromadex stock?
CDXC stock was bought by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., BlackRock Inc., Tieton Capital Management LLC, JPMorgan Chase & Co., Charles Schwab Investment Management Inc. and Northern Trust Corp. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried and Stephen R Allen. View Insider Buying and Selling for Chromadex.
How do I buy shares of Chromadex?
Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chromadex's stock price today?
One share of CDXC stock can currently be purchased for approximately $4.01.
How big of a company is Chromadex?
Chromadex has a market capitalization of $223.44 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe.View Additional Information About Chromadex.
What is Chromadex's official website?
How can I contact Chromadex?
Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]
MarketBeat Community Rating for Chromadex (NASDAQ CDXC)
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
